Fennec Pharmaceuticals Inc. FENC
Set alert
10.78 USD +0.24 +2.29%
As of Nov 3, 1:06 PM ET
10.22 Day range 10.83
5.65 52-week range 13.25
- YTD
- +40.01%
- 1 year
- +32.61%
- Open
- 10.63
- Prev close
- 10.54
- Mkt cap
- 376.27M
- Vol
- 79.99K
- Avg vol
- 190.64K
- EPS
- -0.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.22
- High
- 10.83
- Forward P/E
- 16.78
- Beta
- 0.27
- Short ratio
- 13.06
- Inst. own
- 54.70%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.08
- 200-d avg
- 6.71
- 1y target
- 13.60
6M chart
Signals (30)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
Newest 20 of 30.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.60 +26.1% upside
Now 10.78
- Target (low)
- 12.00
- Target (mean)
- 13.60
- Target (high)
- 15.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.12 | -0.19 – -0.09 | -0.10 | -20.0% | 8.25M | -15.3% | 4 |
| Next quarter | -0.10667 | -0.20 – -0.04 | 0.41 | -126.0% | 8.57M | -66.3% | 3 |
| Current year | -0.07333 | -0.14 – -0.03 | -0.60 | +87.8% | 47.88M | +125.3% | 3 |
| Next year | 0.06 | -0.39 – 0.49 | -0.07333 | +181.8% | 60.13M | +25.6% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 14, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| May 15, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 4, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 18, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Aug 4, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 21, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 6, 2023 | Cantor Fitzgerald | Maintained | — | Overweight |
| Apr 4, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 31, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jan 26, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Nov 22, 2022 | Cantor Fitzgerald | Upgrade | Neutral | Overweight |
| Oct 20, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 26, 2022 | Wedbush | Maintained | — | Outperform |
| Sep 7, 2022 | Capital One | Initiated | — | Overweight |
| Jun 3, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 21, 2021 | Craig-Hallum | Initiated | — | Buy |
| Apr 19, 2021 | Maxim Group | Initiated | — | Buy |
| Jun 5, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |
| May 15, 2020 | HC Wainwright & Co. | Reiterated | — | Buy |
| Sep 17, 2018 | Wedbush | Maintained | Outperform | Outperform |
| Mar 12, 2018 | Wedbush | Initiated | — | Outperform |
| Feb 20, 2018 | HC Wainwright & Co. | Initiated | — | Buy |